Navigation Links
Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
Date:3/27/2013

tudy is predicated on a prospective subgroup analysis conducted in the Phase 2b PEARL-SC study, which was reported in July 2012. In this analysis, a significant improvement in SRI-8 was observed in patients who received subcutaneous blisibimod (200mg QW) compared to those treated standard steroid therapy (N=95, 41.7% versus 10.4% respectively, p<0.001). This finding was corroborated by the separate analysis of SRI-8 responder rates conducted in the entire study population (N=547). The CHABLIS-SC1 study was reviewed by the US Food and Drug Administration as part of an "End of Phase 2" meeting in September 2012.

"The initiation of the CHABLIS-SC1 study marks a critical milestone for Anthera. The insight from our Phase 2b clinical study supports our belief that blisibimod may be a highly effective treatment option for the more severely ill lupus patients compared to currently available therapeutics," said Colin Hislop , MD, Anthera's Chief Medical Officer. "We are excited to advance blisibimod's development. Today we have taken another step towards making a much needed treatment available for this unpredictable and devastating disease."

About B-Cell Activating Factor (BAFF) and blisibimod

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on the potential positive role on BAFF inhibitors in treating lupus and rheumatoid arthritis with concomitant decreases in B-cells, plasma cells and autoantibodies. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel protein compromised of high-affinity BAFF binding domains fused to a human Fc domain,
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
(Date:12/17/2014)... Revenue and earnings above the previous year - ... In the past 2013/14 fiscal year (ended 30 September ... 4.287 billion (last year: EUR 4.190 billion) despite unfavorable currency ... million. "Overall, 2013/14 was a successful fiscal year for the ... CEO of Carl Zeiss AG. "Thanks to our broad portfolio ...
(Date:12/17/2014)... 2014 , The ... hub of information concerning the biopharmaceutical Group,s national and international ... addition to the recently launched institutional website that is receiving ... enriched by a new chapter in the fascinating story of ... detailed and panoramic hub on the world of clinical research, ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... 2011 CVS Caremark Corporation (NYSE: CVS ... Executive Officer, will be making a presentation to investors ... June 1, 2011. Mr. Merlo is scheduled to present ... An audio webcast of the presentation will be ...
... U.S. Food and Drug Administration today approved Edurant (rilpivirine) ... of HIV-1 infection in adults who have never taken ... ) Edurant belongs to a class ... The drug works by blocking HIV viral replication. Edurant ...
Cached Medicine Technology:FDA Approves New HIV Treatment 2FDA Approves New HIV Treatment 3
(Date:12/21/2014)... 2014 The Oncology Institute of Hope and ... Ana and Whittier offices. The Hope for the Holidays Toy ... patients and their families during the holiday season. This year, ... 70 children between both offices. This event continues to be ... community service team, store managers and assistant managers came out ...
(Date:12/20/2014)... BambooIndustry.com is a leading eco-friendly bamboo flooring ... bamboo flooring promotion for the coming 2015. , ... and offers the best bamboo products and services ... all customers can enjoy a special discount, up ... BambooIndustry.com from press releases. , The bamboo flooring ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 ... the healthcare sector have benefited the Massage Services ... the discretionary characteristics of industry products, the anticipated 1.0% ... five-year period has provided consumers with the means to ... that have received a massage in a given year ...
(Date:12/20/2014)... 20, 2014 The print component of ... a distribution of approximately 160,000 copies and an estimated ... through a vast social media strategy and across a ... explore the digital version of the campaign, click ... interview with the ladies of CTV’s The Social. ...
(Date:12/20/2014)... December 20, 2014 The Doctor’s Office Urgent ... the better part of a decade. They’ve treated over ... better, faster healthcare alternative to the Paramus area. ... three new additions to their staff of top-notch board certified ... Zeiger MD. These new doctors will work tirelessly ...
Breaking Medicine News(10 mins):Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2
... , New York, N.Y. -- The changes in brain ... detectable in children as young as 6 months, according ... Journal of Psychiatry . While core behaviors associated with ... be identified after a baby,s first birthday, researchers found ...
... the initial steps that occur in the body when type ... adult. The analysis comes from a team of researchers ... have expertise both in the laboratory and in treating patients. ... 48 hours of their diagnosis with type 1 diabetes, an ...
... THURSDAY, Feb. 16 (HealthDay News) -- When it comes ... weight training may be more effective than stretching or ... "reconfirm our notions that exercise plays an important part ... outside expert, Dr. Nora Chan, director of the Movement ...
... cancer, which killed 15,000 American women last year, is ... of Wayne State University School of Medicine researchers recently ... cancer patients. The "freeze and destroy" technique is ... Peter Littrup, M.D., professor of radiology in the School ...
... HealthDay Reporter , THURSDAY, Feb. 16 (HealthDay ... struggle with heart failure, experts say new treatments have ... for these patients. "The present environment for heart ... that will truly remove the term ,failure, from the ...
... carbon nanoparticles shows potential to enhance treatment for head-and-neck ... new research by Rice University and the University of ... a path for further research into therapy customized to ... nanoparticles to encapsulate chemotherapeutic drugs and sequester them until ...
Cached Medicine News:Health News:Researchers see differences in Autism brain development as early as 6 months 2Health News:As diabetes emerges, researchers track disease's first steps 2Health News:As diabetes emerges, researchers track disease's first steps 3Health News:As diabetes emerges, researchers track disease's first steps 4Health News:Weight Training May Help Parkinson's Patients Retain Function 2Health News:Wayne State proves targeted tumor freezing therapy increases ovarian cancer survival 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 3Health News:Nanoparticles may enhance cancer therapy 2Health News:Nanoparticles may enhance cancer therapy 3Health News:Nanoparticles may enhance cancer therapy 4
Large....
These products are supplied non-sterile and must be sterilized before use. For insertion through the smokevac and nezhat-dorsey trumpet valve in conjunction with the universal instrument insert adapt...
... Utilizing breakthrough electro-optical and rotary ... SUPRA is capable of obtaining ... pupils as narrow as 2.0mm. ... precise diagnostic results when dealing ...
Sterile perfluorocarbon for intraocular Application....
Medicine Products: